Resolian
Resolian traces its roots to Drug Development Solutions, established in Fordham, UK in 1997, and has since evolved into a globally-harmonized leader in pharmaceutical analytical and materials sciences laboratory services.
With facilities in the U.S., U.K., Australia, and China, the Company enables preclinical and clinical trial sponsors to seamlessly conduct small or large molecule studies around the world. Built through a series of thoughtful acquisitions and greenfield investments, Resolian has been continuously supported by investments in technology, space, and expertise. The Company today is well-positioned to meet growing global demand for client-centric, advanced scientific, high-quality, flexible, and time-sensitive clinical trial analytical and production batch release characterization services.
Keys to Success
Ampersand’s 2021 investment came at a pivotal moment for Alliance Pharma Inc., a well-respected US-based bioanalytical CRO in Malvern, PA. The company’s founder wished to transition from day-to-day operations, opening the door to a global build-out and long-term growth. Ampersand helped chart a path toward geographic expansion, global multi-site integration, and enhanced scientific depth. The strategy quickly gained pace.
In 2022, the acquisition of Drug Development Solutions (DDS), with sites in both Fordham and Sandwich, UK, established Resolian’s European footprint and facilitated KKR’s co-investment.
In Australia, where early-phase clinical trials are in high demand, given fast regulatory approval timelines and R&D tax incentives, Resolian partnered with previously-trained Alliance Pharma local scientists to build and launch a greenfield Brisbane-based laboratory. The lab, which became audit-certified and fully operational in early 2023, quickly became a strategic bridge to the fast-growing Asia-Pacific sponsor markets.
The team also set its sights on China, an increasingly important country for global drug pipeline sourcing and trial sponsors. In November 2023, Resolian acquired Denali MedPharma, a lab founded by US-trained scientists operating to Western standards. A strong cultural and scientific alignment facilitated Denali’s immediate integration, western pharma site audits, program initiation, and contributions to Resolian’s ideal pan-planet network.
In May 2023, the company was rebranded “Resolian”, leveraging the company’s commitment to being “Resolute”, “Resolving” any client matters, and having the highest “Resolution with analytical techniques.
From the outset, Ampersand and Resolian shared a vision: build a differentiated global platform that could surpass much larger CRO client experiences via responsiveness and the client-first culture of a scientific specialist provider.
“Resolian’s expansion wasn’t just about adding locations — it was about strategically elevating its global scientific capabilities and customer support. Each acquisition and new site brought unique expertise, and by continuing to harmonize our processes across continents, we aim to provide consistent, high-quality bioanalytical, biomarker, and analytical material science services to our clients as their projects move across the development continuum. Ampersand’s support has helped position Resolian to meet clients’ needs on a global scale.” –Rob Stachlewitz, CEO, Resolian
Today, Resolian is one of the only specialty bioanalytical service providers with small and large molecule lab operations in virtually every key clinical trial geography. Its clients — from emerging biotech to global pharma — benefit from consistent methods, harmonized processes, and the ability to seamlessly transfer assays across continents.
By expanding its scientific capabilities and scaling its geographic reach without sacrificing service quality, Resolian has positioned itself as a true partner to global drug developers. With continued backing from Ampersand, the company is poised to grow its leadership role in bioanalytical laboratory testing and help resolve complex challenges, wherever trials are run.
“Our expansion into the U.K., China, and Australia was a strategic and well-supported initiative. Through Ampersand’s partnership, Resolian established a strong foundation to operate globally while maintaining high-quality local delivery.” –Frank Li, Founder and Resolian Board of Directors
Disclosure: The case study and results included are for illustration purposes only and may not be typical. The case study should not be considered specific investment advice, do not take into consideration a specific situation, and are not intended to make an offer or solicitation for the sale or purchase of any securities or investment strategies. Investments involve risk and are not guaranteed. Case study testimonials were provided by clients between May 2024 – July 2024. The client was not compensated, nor are their material conflicts of interest that would affect the given testimony. The testimony may not be representative of the experience of other current clients and does not provide a guarantee of future performance success or similar services.
The statements provided herein are made by certain founders or executives of Ampersand’s past and/or current portfolio companies. Certain statements made herein are considered “testimonials” and express approval, support, or a recommendation of Ampersand, or describe the individual’s experience with Ampersand. The individual has not been directly compensated for making these statements. However, a portfolio company in which the individual held a significant equity interest may have received financial investment from Ampersand through one or more funds managed by Ampersand. As such, the individual may have an indirect financial interest in the success of Ampersand’s activities or in presenting Ampersand in a favorable light. Additionally, the individual may be an Operating Partner or Executive Advisor with Ampersand. As an Operating Partner or Executive Advisor, the individual performs certain services for Ampersand and may be compensated for providing these services. These potential conflicts of interest should be considered by prospective investors when evaluating the individual’s testimonial.
The individual’s statements reflect past, subjective experiences and are not indicative of future performance or success. Any testimonial made by the individual does not guarantee that future clients or portfolio companies will have similar experiences or achieve similar outcomes. Investment outcomes are subject to numerous risks and uncertainties, and there can be no assurance that any investment will achieve its objectives or that investors will not experience losses. This case study should not be considered specific investment advice, does not take into account any specific situation, and is not intended to make an offer or solicitation for the sale or purchase of any securities or investment strategies. Investments involve risk and are not guaranteed.